|
Synonyms: BAY-2976217 | BAY2976217 | IONIS FXI-LRx | IONIS-FXI-LRx
Compound class:
Nucleic acid
Comment: Fesomersen (IONIS-FXI-LRx) is a conjugated antisense oligonucleotide that selectively inhibits the expression of factor XI [1]. It is being explored as an anticoagulation therapy.
We provide the basic nucleotide sequence, without the modifications outlined in the INN record for this drug. |
| No information available. |
Summary of Clinical Use ![]() |
| Fesomersen was progressed to determine safety and efficacy as an anticoagulation therapy to reduce clotting in patients at high risk of thrombosis. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03582462 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers | Phase 1 Interventional | Ionis Pharmaceuticals, Inc. | ||
| NCT04534114 | Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug | Phase 2 Interventional | Bayer | ||